BiotechTube

Darinaparsin

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hematologic Neoplasms

Conditions

Hematologic Neoplasms, Bone Marrow Neoplasms, Non-Hodgkin's Lymphoma

Trial Timeline

Dec 1, 2006 → Apr 1, 2012

NCT ID
NCT00421213

About Darinaparsin

Darinaparsin is a phase 2 stage product being developed by Alaunos Therapeutics for Hematologic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00421213. Target conditions include Hematologic Neoplasms, Bone Marrow Neoplasms, Non-Hodgkin's Lymphoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT01139346Phase 1Completed
NCT00423306Phase 2UNKNOWN
NCT00421213Phase 2Completed

Competing Products

20 competing products in Hematologic Neoplasms

See all competitors
ProductCompanyStageHype Score
120 mg LY2784544Eli LillyPhase 2
52
RLYB116 for InjectionRallybioPhase 1
25
DS3790a + Combination drug + Combination drugDaiichi SankyoPhase 1/2
41
IsavuconazoleAstellas PharmaPhase 2
52
isavuconazonium sulfate - intravenous + isavuconazonium sulfate - oralAstellas PharmaPhase 1
33
DSP-5336 + [14C]-DSP-5336Sumitomo PharmaPhase 1
33
BBI608 + Dexamethasone + Bortezomib + Imatinib + IbrutinibSumitomo PharmaPhase 1
33
Venetoclax + ethinyl estradiol/levonorgestrelAbbViePhase 1
33
ABT-888 + TemozolomideAbbViePhase 1
33
ABBV-101AbbViePhase 1
33
elotuzumab + lenalidomide + dexamethasone oral + dexamethasone injectionAbbViePhase 2
52
Capivasertib + RabeprazoleAstraZenecaPhase 1
33
AZD9829 + AZD9829AstraZenecaPhase 1/2
41
ridaforolimusMerckPhase 2
52
Pembrolizumab/vibostolimab coformulationMerckPhase 2
52
NemtabrutinibMerckPhase 1
33
Ondansetron + AprepitantMerckPhase 2
52
NemtabrutinibMerckPhase 2
52
ARQ 621MerckPhase 1
33
NemtabrutinibMerckPhase 1
33

Other Products from Alaunos Therapeutics

doxorubicin in combination with palifosfamide-tris + doxorubicin in combination with placeboPhase 3
69
Carboplatin + Palifosfamide-tris + Etoposide + CarboplatinPhase 3
69
Palifosfamide Tris and Doxorubicin + DoxorubicinPhase 2
44
Ad-RTS-hIL-12 + Veledimex + Cemiplimab-RwlcPhase 2
44
palifosfamidePhase 2
44